OptiNose (NASDAQ:OPTN) released its quarterly earnings results on Tuesday. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.18), Morningstar.com reports.
OptiNose (NASDAQ OPTN) opened at $17.11 on Wednesday. OptiNose has a 52 week low of $15.01 and a 52 week high of $21.50.
Separately, Piper Jaffray Companies set a $28.00 price objective on shares of OptiNose and gave the company a “buy” rating in a research note on Monday, January 15th.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/14/optinose-optn-issues-earnings-results-misses-expectations-by-0-18-eps.html.
OptiNose Company Profile
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.